Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb:30:9-16.
doi: 10.1016/j.conb.2014.08.004. Epub 2014 Sep 15.

Illuminating circuitry relevant to psychiatric disorders with optogenetics

Affiliations
Review

Illuminating circuitry relevant to psychiatric disorders with optogenetics

Elizabeth E Steinberg et al. Curr Opin Neurobiol. 2015 Feb.

Abstract

The brain's remarkable capacity to generate cognition and behavior is mediated by an extraordinarily complex set of neural interactions that remain largely mysterious. This complexity poses a significant challenge in developing therapeutic interventions to ameliorate psychiatric disease. Accordingly, few new classes of drugs have been made available for patients with mental illness since the 1950s. Optogenetics offers the ability to selectively manipulate individual neural circuit elements that underlie disease-relevant behaviors and is currently accelerating the pace of preclinical research into neurobiological mechanisms of disease. In this review, we highlight recent findings from studies that employ optogenetic approaches to gain insight into normal and aberrant brain function relevant to mental illness. Emerging data from these efforts offers an exquisitely detailed picture of disease-relevant neural circuits in action, and hints at the potential of optogenetics to open up entirely new avenues in the treatment of psychiatric disorders.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement

K.D. and R.C.M. are co-founders of a company, Circuit Therapeutics, Inc., the goals of which are to use optogenetics to improve the drug development process and to develop novel devices to treat disorders of the peripheral and central nervous systems. They are both on the scientific advisory board for Circuit Therapeutics, Inc.

Similar articles

Cited by

References

    1. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355. - PMC - PubMed
    1. Nestler EJ. Antidepressant treatments in the 21st century. Biol Psychiatry. 1998;44:526–33. - PubMed
    1. Roth BL. Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? Dialogues Clin Neurosci. 2006;8:303–9. - PMC - PubMed
    1. Hyman SE. Revitalizing psychiatric therapeutics. Neuropsychopharmacology. 2014;39:220–9. A frank and insightful discussion of the practical and scientific obstacles to developing new therapies for psychiatric disorders, with a focus on new technologies that have the potential to circumvent these challenges. - PMC - PubMed
    1. Weaver DF, Weaver CA. Exploring neurotherapeutic space: how many neurological drugs exist (or could exist)? J Pharm Pharmacol. 2011;63:136–9. - PubMed

Publication types